In an exclusive interview with Alexandria (Sasha) Latypova, MBA, who is a former pharmaceutical executive and independent analyst. She has made it clear with her prior reports on TrialSite News that deaths reported in VAERS after COVID-19 vaccination are not randomly distributed according to manufacturing lots as they are with influenza vaccines; instead, they are aggregated in specific “hot lots.”